Annovis Bio (ANVS) Liabilities and Shareholders Equity (2019 - 2026)

Annovis Bio has reported Liabilities and Shareholders Equity for 8 years, with the latest figure at $16.2 million in Q1 2026.

• Quarterly Liabilities and Shareholders Equity fell 39.25% year-over-year to $16.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $76.0 million (up 26.47% YoY) and the FY2025 annual result came in at $21.1 million, up 51.39% from the prior year.
• Liabilities and Shareholders Equity fell to $16.2 million in Q1 2026 per ANVS's latest filing, from $21.1 million in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $44.1 million in Q1 2022 and troughed at $5.0 million in Q2 2024.
• A 5-year average of $21.8 million and a median of $21.1 million in 2025 frame the typical range for Liabilities and Shareholders Equity.
• The sharpest annual moves came in 2022 and 2024: Liabilities and Shareholders Equity soared 639.28% in 2022, then plunged 77.88% in 2024.
• Over 5 years, Liabilities and Shareholders Equity stood at $36.0 million in 2022, then slumped by 71.66% to $10.2 million in 2023, then soared by 36.42% to $13.9 million in 2024, then jumped by 51.39% to $21.1 million in 2025, then fell by 22.95% to $16.2 million in 2026.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $16.2 million, $21.1 million, and $17.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.